Cantor Fitzgerald Lifts PT on Eli Lilly and Company (LLY) on Q1 Earnings Call

Eli Lilly and Company (NYSE:LLY) is one of the best strong buy stocks to invest in according to billionaires. Cantor Fitzgerald lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,230 from $1,205 on May 1, reaffirming an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 call highlighted solid OUS Mounjaro demand with potential upside to raised guidance and encouraging early Foundayo ramp commentary. It also cited improved earnings leverage supporting higher EPS expectations and multiple catalysts, including a potential 2H acceleration and anticipation of retatrutide, helping sustain engagement.

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

In another development, Eli Lilly and Company (NYSE:LLY) announced on April 27 the signing of a definitive agreement for it to acquire Ajax. Ajax is a biopharmaceutical company that develops next-generation JAK inhibitors for patients with myeloproliferative neoplasms, and its lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously been treated with a Type I JAK2 inhibitor.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.